Prelude Therapeutics reported FY 2025 revenue of USD 12.14 million, up 73%. FY 2025 R&D expense fell 20% to USD 94.3 million, driven by lower stock-based compensation and reduced costs tied to discontinued clinical trials. FY 2025 G&A expense decreased 22% to USD 22.41 million, primarily due to lower stock-based compensation and employee-related expenses. FY 2025 net loss narrowed 22% to USD 99.5 million, or USD 1.29 per share. The company ended FY 2025 with USD 106.4 million in cash, cash equivalents, restricted cash and marketable securities and said its cash runway is expected into Q2 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prelude Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603100701PRIMZONEFULLFEED9668681) on March 10, 2026, and is solely responsible for the information contained therein.